Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Improving Variance and Confidence Interval Estimation in Small-Sample Propensity Score Analyses: Bootstrap Versus Asymptotic Methods.

Statistics in medicine·2026
Same author

Prognostic value of [<sup>18</sup>F]fluorodeoxyglucose PET/CT in esophageal cancer patients treated with anti-PD-1 inhibitors.

BMC medical imaging·2026
Same author

Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC.

Frontiers in oncology·2026
Same author

The Implication of Failure Patterns After Neoadjuvant Chemoradiation Therapy With Small Involved Field in Esophageal Squamous Cell Carcinoma.

Practical radiation oncology·2026
Same author

Phase II Efficacy and Safety of Pembrolizumab with Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients with Untreated, Asymptomatic Brain Metastasis (PHOEBS).

Cancer research and treatment·2026
Same author

Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experience.

International journal of cancer·2026
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
查看所有相关文章

相关实验视频

Updated: Jun 9, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.5K

随机二期癌症临床试验验验证预测生物标志物

Baoshan Zhang1, Jong-Mu Sun2, Myung-Ju Ahn2

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27705, USA.

Biomedicines
|October 26, 2024
PubMed
概括
此摘要是机器生成的。

这项研究引入了设计和分析II期癌症临床试验的新方法,以验证预测生物标志物. 该方法确保了生物标志物分层试验的稳健的样本大小选择和分析策略.

关键词:
互动互动互动互动互动.逻辑回归的逻辑回归样本大小计算的计算一个分层的随机化试验.

更多相关视频

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

相关实验视频

Last Updated: Jun 9, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

科学领域:

  • 在瘤学瘤学.
  • 临床试验设计 临床试验设计
  • 生物标志物的验证

背景情况:

  • 使用生物标志物的癌症临床试验的设计需要仔细考虑试验阶段,生物标志物类型和验证状态.
  • 二期试验对于验证预测生物标志物以指导向治疗至关重要.

研究的目的:

  • 提出设计和分析II期癌症临床试验的方法,重点是验证预测生物标志物.
  • 为临床试验环境中生物标志物验证提供实用方法.

主要方法:

  • 建议采用随机试验设计,根据生物标志物状态对患者进行分层,并将他们分配到向或非向治疗中.
  • 瘤反应是通过相互作用测试验证生物标志物的主要终点.
  • 开发了一种样本大小计算方法,考虑了逻辑转换和原始响应率.

主要成果:

  • 拟议的样本大小方法应用于现实世界随机二期试验.
  • 模拟显示了测试统计和样本大小方法在各种场景中的强大性能.

结论:

  • 开发的方法为在II期癌症试验中验证预测生物标志物的实用框架.
  • 模拟结果支持所选择的相互作用模型,并为生物标志物分层试验中的样本大小和分析提供指导.